Immunome (IMNM) Total Liabilities (2019 - 2026)

Immunome's Total Liabilities history runs 8 years deep, the most recent figure standing at $31.1 million for Q1 2026.

• Quarterly Total Liabilities fell 12.54% year-over-year to $31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.1 million (down 12.54% YoY) and the FY2025 annual result came in at $48.8 million, down 17.32% from the prior year.
• Total Liabilities was $31.1 million for Q1 2026 at Immunome, down from $48.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $87.1 million in Q3 2023 and bottomed at $7.4 million in Q4 2022.
• A 5-year average of $33.6 million and a median of $34.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities jumped 1067.05% — and 2024, when it slumped 51.78%.
• Immunome's Total Liabilities stood at $7.4 million in 2022, then surged by 287.64% to $28.7 million in 2023, then soared by 106.14% to $59.1 million in 2024, then declined by 17.32% to $48.8 million in 2025, then sank by 36.32% to $31.1 million in 2026.
• Business Quant data shows IMNM's Total Liabilities at $31.1 million in Q1 2026, $48.8 million in Q4 2025, and $35.5 million in Q3 2025.